The Daily

Italy in March is peak “shoulder season”: the crowds haven’t fully landed, but the calendar wakes up. This expat-focused roundup is useful because it clusters the month into a few high-signal moments. The most practical tip: the Giornate FAI di Primavera (mid‑March) — the Italian Environmental Fund opens hundreds of normally closed villas, gardens and historical sites for a small donation, often with volunteer guides. Add International Women’s Day (March 8), when (per the article) state museums and archaeological sites run special access initiatives, and you have a low-cost culture week that’s hard to beat. For sports-driven travel: Italy vs. England in the Six Nations (Rome, March 7) turns the Stadio Olimpico + the city into a two-day festival. If you plan a weekend, book trains/hotels early: March is calm, but the good deals disappear first.

Due giorni al Forte Marghera per un percorso di degustazione tra Champagne e vini internazionali, con oltre 100 espositori da più di 20 Paesi (masterclass, talk e abbinamenti gastronomici). Orari: sabato 11–21, domenica 10–20. Un’idea perfetta se vuoi Venezia “senza gondola‑stereotipo”: laguna, bici, e poi bollicine.

The most interesting detail here isn’t just the headline number — it’s the coalition. Neura Robotics (Germany) is said to be in talks for a ~€1B round that could include Tether, the USDT stablecoin issuer. If it happens, it’s a sharp example of AI hardware ambition meeting crypto’s balance sheet. Neura’s pitch is “robots with onboard AI”: a natural-language-driven humanoid (the 4NE1 Mini), a quadruped for rough terrain, plus robotic arms and logistics bots. The subtext: the next AI arms race is physical — and capital-intensive. Even if the rumored valuation is “only” ~€4B (down from earlier chatter), a mega-round would signal that investors believe humanoids are moving from demo videos to order books.

Richter’s transformation (CLL/SLL turning into an aggressive DLBCL) is one of the bleakest lanes in hematology: often chemorefractory, with outcomes that feel stuck in a bad decade. This cohort study reports mosunetuzumab (a CD20×CD3 bispecific) in 20 relapsed/refractory RT patients. Safety looks manageable: cytokine release syndrome occurred in 65%, but was almost entirely grade 1–2 and clustered in cycle 1, with no discontinuations due to adverse events. Efficacy: 40% overall response, 20% complete responses — and the meaningful bit is durability: two CRs lasting >20 months without further therapy, plus patients bridging to allogeneic transplant in CR. Median PFS/OS were 3.4 and 10.2 months, but the tail matters. For RT, “tolerable with a real CR tail” is the kind of signal that earns combination trials.

An in‑vitro deep-dive into how blinatumomab (CD19×CD3) drives effector function across conventional αβ and unconventional γδ T cells. Fresh αβ (especially CD8+) showed stronger early killing and cytokine output, while γδ performance varied by donor — but zoledronate‑expanded Vγ9Vδ2 γδ T‑cell lines reached cytotoxicity comparable to expanded αβ lines. The authors also note different activation signatures (e.g., CD3 down-modulation in αβ but not γδ), hinting at distinct exhaustion/AICD dynamics. It’s a “why it works / why it fails” paper that quietly supports future combo concepts: engineered or expanded γδ cells as a way to sustain bispecific-driven cytotoxicity under tougher tumor load conditions.

Der Falter erinnert (zurecht) daran, dass der Wiener Eistraum langsam Richtung Finale rutscht – und dass es dort erstaunlich kindertauglich ist, ohne dass man gleich im „Profi‑Rundkurs“ untergeht. Für Kinder gibt’s zwei eigene Eisflächen: eine 140 m² große Fläche, die gratis genutzt werden kann (ab 17:00 wird sie zur Eisstockbahn), plus eine kleine Fläche für die ganz Kleinen nahe dem Verleih – ebenfalls kostenfrei. Wenn ihr sowieso „nur kurz“ wollt: genau dafür ist es perfekt.

Wer am Wochenende eine Indoor‑Option sucht, die nicht „nur Museum“ ist: Bei der Familienführung durch die Kapuzinergruft begleitet ein fiktiver Baron Kinder ab sieben Jahren durch die Habsburger‑Geschichte – entlang der kunstvollen Särge, mit Story statt Schulbuch. Reservierung wird empfohlen.

Wienerin liefert einen erfreulich konkreten Überblick über neue Lokale, ohne dass alles nach „Hype“ klingt. Highlight: Dampha Kitchen hat nach fünf Jahren Pop‑up endlich eine fixe Adresse am Yppenplatz. Khalifa Dampha übersetzt seine Biografie (Gambia/Spanien) in eine Karte, die Sharing-tauglich ist: Peanut Butter Chicken, Jollof Rice, Empanadas, Tacos mit afrikanischem Twist. Ebenfalls spannend: Das Melt in der Leopoldstadt versucht Zero‑Waste ernst zu nehmen (vom Einkauf bis zum letzten Krümel), aber mit Comfort‑Food‑Karte (Burger, Ribs, vegetarisch) statt moralischem Zeigefinger. Und wer türkische Küche jenseits Döner-Klischee will: Kübey am Rudolfsplatz setzt auf moderne Meze + Naturwein.

One of the biggest quiet constraints in cell therapy isn’t science — it’s operations. PharmExec highlights a new company, NexCure, launching with a $19M Series A to attack the CAR‑T delivery bottleneck: roughly 200 of ~6,100 U.S. hospitals administer CAR‑T today, which effectively hard-caps how many eligible patients can actually receive it. NexCure’s model pairs purpose-built outpatient clinics with a proprietary “operating system” (decision support, remote monitoring, operational intelligence) to standardize protocols and reduce variability. The strategic angle is bigger than oncology: as CAR‑T indications expand into autoimmune disease, the system needs to scale without turning every patient journey into a bespoke academic‑center project.

In the same roundup: Cognito’s $105M Series C to push its at‑home Alzheimer’s device (coordinated visual + auditory stimulation) toward pivotal readout and a targeted 2027 U.S. entry. The bet is that “non‑drug” neuroprotection can scale faster if it’s prescribed, used at home, and doesn’t depend on infusion-center throughput.

The NBA’s “Starting 5” sets up tonight’s Lakers–Nuggets with a very specific piece of history on the line: LeBron James is three made field goals away from passing Kareem Abdul‑Jabbar for the most in league history. The number is almost funny in its simplicity — made shots — but that’s why it lands. It’s a longevity record that also encodes adaptability: LeBron’s scoring has survived four tactical eras, from early‑career slashing to mid‑range control and now modern spacing. The game itself matters too: both teams are jammed in the West race, and the matchup stacks stars on top of stars.